Skip to main content

Table 1 Pertussis vaccine efficacy studies

From: Pertussis re-emergence in the post-vaccination era

Study (year) Country Type of analysis Included partecipans Dose schedule Type of vaccine Efficacy of vaccine (95% CI)
AHGSPV 1988 USA Double bind parallel group RCT Age 5 to 11 months 2 doses (entry + 8 to 12 week later) aP: JNIH7 78% (57-88%)
aP: JNIH6 78% (58-89%)
Trollfors 1995 Sweden Double bind parallel group \ RCT Full term, healthy infants 3 doses (3, 5, 12 months) DTaP: Amvax 71% (63-78%)
Greco 1996 Italy Double bind parallel group RCT Age 6 to 12 weeks and weight >3rd percentile 3 doses (6 to 12, 13 to 20, and 21 to 28 weeks) DTaP: SKB 84% (76-89%)
DTaP: CB 84% (76-90%)
DTwP: CON 36% (13-50%)
Gustafsson 1996 Sweden Double bind parallel group RCT Age 2 to 3 months 3 doses (2, 4, 6 months) DTaP: SKB 59% (51-66%)
DTaP: CON 85% (81-89%)
DTwP: CON 48% (37-58%)
Simondon 1997 Senegal Parallel group RCT Age 2 months 3 doses (2, 4, 6 months) DTaP: Pasteur-Merieux 85% (66-93%)
DTwP: Pasteur-Merieux 96% (86-99%)
Olin 1997 Sweden RCT Age 2–3 months 3 doses (3, 5, 12 months or 2, 4, 6 months) 3-component DTaP 72%
5-component 85%
DTaP  
DTwP 89%
PVSG 1998 Germany Parallel group RCT Age 2 to 4 months 4 doses (2 to 4, 4 to 6, 6 to 8, 12 to 14, and 15 to 18 months) DTaP: Lederle/ Takeda 79% (72-85%)
DTwP: Lederle 84% (77-89%)
Ward 2006 USA Multicenter, double-blind RCT Age 15 to 65 years A single dose of a 3-component aP vaccine aP (PT, FHA, PRN) 92% (32-99%)
  1. Abbreviations.
  2. RCT: randomised controlled trial.
  3. aP: acellular pertussis vaccine.
  4. DTaP: diphtheria-tetanus-acellular pertussis vaccine.
  5. DTwP: diphtheria-tetanus-whole-cell pertussis vaccine.
  6. SKB: SmithKline Beecham.
  7. CB: Chiron-Biocine.
  8. CON: Connaught.